欧洲糖尿病行业市场前景及投资研究报告-外文版培训课件

POLITICS

&

SOCIETYDiabetesinEuropeCHAPTER

01GlobaloverviewEstimatednumberofdiabeticsworldwidein2021,2030,and2045(inmillions)Diabeticsworldwide2021,2030,and2045900800700600783643537500400300200100020212030*2045*4Description:Thenumberofdiabeticsworldwidein2021was537million.Thatnumberisexpectedtogrowuntilatleasttheyear2045.Theprojectednumberofdiabeticsisexpectedtoreach783millionbythattime.Withanincreasednumberofdiabetics,theprevalenceofdiabetesisalsoprojectedtoincreasetoaround12percentby2045.ReadmoreNote(s):Worldwide;20-79yearsSource(s):InternationalDiabetesFederationPercentageofdiabeticsintheglobaladultpopulationin2021,2030,and2045Diabeticsprevalenceworldwide2021,2030.and204514%12.2%12%11.3%10.5%10%8%6%4%2%0%20212030*2045*5Description:Around10.5percentoftheglobaladultpopulationsufferedfromdiabetesin2021-bytheyear2045thisnumberisexpectedtorisetoover12percent.Diabetes,ordiabetesmellitus,referstoagroupofmetabolicdisordersthatresultinchronichighbloodsugarlevels.Diabetescanleadtoserioushealthcomplications,suchascardiovasculardisease,chronickidneydisease,andstrokeandisnowamongthetoptenleadingcausesofdeathworldwide.

ReadmoreNote(s):Worldwide;20-79yearsSource(s):InternationalDiabetesFederationNumberofdiabeticsworldwidein2021,byregion(inmillions)Numberofdiabeticsworldwidebyregion2021Numberofdiabeticsinmillions050100150200250WesternPacificSoutheastAsia20690MiddleEastandNorthAfricaEurope7361NorthAmericaandCaribbeanSouthandCentralAmericaAfrica5132246/statistics/241802/number-of-diabetics-worldwide-by-regionThisstatisticdepictsthenumberofdiabeticsworldwidein2021,sortedbyregion.TheWesternPacificistheregionwiththehighestnumberofdiabeticsworldwide,withsome206millionpersonsagedbetween20and79yearssufferingfromdiabetes.ReadmoreNote(s):Worldwide;20-79yearsSource(s):InternationalDiabetesFederationProjectednumberofdiabeticsworldwidein2045,byregion(inmillions)Projectednumberofdiabeticsworldwidebyregion2045Numberofdiabeticsinmillions050100150200250300WesternPacificSoutheastAsia260152MiddleEastandNorthAfricaEurope13669NorthAmericaandCaribbeanAfrica6355SouthandCentralAmerica497Description:By2045,theWesternPacificregionisforecasttohavethehighestnumberofdiabeticpeopleworldwide,withsome260millionpeopleagedbetween20and79years.

ReadmoreNote(s):Worldwide;2021;20-79yearsSource(s):InternationalDiabetesFederationPrevalenceofdiabetesamongadultsinselectedcountriesasof2021Diabetesprevalenceadultsinselectedcountries2021Prevalenceofdiabetes0%2%4%6%8%10%12%14%16%18%MexicoTurkey16.9%15.9%Spain14.8%UnitedStatesChina13.6%13%13%PortugalChile12.7%Japan11.8%Malta11.2%CanadaBrazil10.5%10.5%GermanyBulgaria10%9.9%8Description:In2021,almost17percentofadultsbetweentheagesof20and79haddiabetesinMexico.OtherselectedcountrieswithahighprevalenceofdiabetesthatyearincludedTurkey,Spain,andtheUnitedStates.Diabetesisametabolicdiseasethatcauseshighbloodsugarlevels.ReadmoreNote(s):OECD;20-79yearsSource(s):InternationalDiabetesFederationNumberofdeathsbeforetheageof60duetodiabetesworldwidein2021,byregion(inthousands)Numberofdiabetesdeathsworldwide2021,byregion800717.4700600500428.64003002001000306301.2199.9144.786.7WesternPacificMiddleEastandNorthAfricaAfricaSouthEastAsiaNorthAmericaandCaribbeanEuropeSouthAmericaandCentralAmerica9Description:In2021,therewereestimatedtobearound301,200deathsamongthoseaged60yearsandyoungerduetodiabetesinSouthEastAsia.SouthAmericaandCentralAmericahadthelowestnumberofdiabetes-relateddeathsthatyear.

ReadmoreNote(s):WorldwideSource(s):InternationalDiabetesFederationHealthcareexpenditureduetodiabetesworldwidein2021,byregion(inbillionU.S.dollars)Healthcareexpenditureduetodiabetesworldwidebyregion2021ExpenditureinbillionU.S.dollars050100150200250300350400450NorthAmericaandCaribbeanWesternPacific414.5241.3Europe189.3SouthandCentralAmericaMiddleEastandNorthAfricaAfrica65.332.612.610.1SoutheastAsia10Description:TheNorthAmericanandCaribbeanregionspentsome415billionU.S.dollarsonhealthcareforpeoplewithdiabetesin2021.HealthcareexpenditureswerethelowestinAfricaandSoutheastAsiathatyear.

ReadmoreNote(s):Worldwide;20-79yearsSource(s):InternationalDiabetesFederationConsumptionofanti-diabeticdrugsinselectedcountriesin2022(inDDDper1,000people)Consumptionofanti-diabeticdrugsbyselectcountry2022DDDperthousandpeopleperday60

80

10002040120140160180CanadaFinland*154.7105.6GreeceCzechRepublic*Turkey*Germany*SloveniaUnitedKingdom*Spain98.497.596.393.691.69088.687.485France*PortugalSweden80.579.7Chile11Description:Thestatisticshowstheconsumptionofanti-diabeticdrugsinselectedOECDcountriesin2022-orlatestyearavailable(2021).Asofthatyear,nearly89defineddailydoses(DDD)ofanti-diabeticdrugsweretakeninSpainper1,000people.

ReadmoreNote(s):Worldwide,OECDSource(s):OECDCHAPTER

02EuropeansituationPrevalenceofdiabetesinadultpopulationinEurope2021,bycountryDiabetesprevalenceamongadultsinEuropein2021,bycountryShareofpopulationwithdiabetes0%2%4%6%8%10%12%14%16%SpainPortugalMalta14.8%13%11.2%GermanyBulgariaItaly10%9.9%9.9%CzechiaFinlandCyprusGreeceLithuaniaPolandHungary9.8%9.7%9.7%9.6%9.5%9.4%9.1%13Description:SpainhadthehighestprevalenceofdiabetesinEuropeamongtheiradultpopulationwith14.8percentlivingwithdiabetes,asof2021,Portugalfollowedwiththesecondhighestshareat13percent.Conversely,IrelandwasthecountrywiththelowestprevalenceofdiabetesinEuropeatfourpercent.ReadmoreNote(s):Europe;2021;20-79yearsSource(s):InternationalDiabetesFederationNumberofchildrenandadolescentswithtype1diabetesinEuropein2021,bycountryType1diabetesamongchildreninEuropein2021,bycountryNumberofchildrenwithdiabetes05,00010,00015,00020,00025,00030,00035,00040,000GermanyUnitedKingdomFrance35,14431,62327,128Spain17,221Italy13,715Poland12,447Sweden9,167NetherlandsFinland6,3935,410BelgiumCzechia4,3304,284RomaniaNorway3,8603,82114Description:In2021,Germanyhadthehighestnumberofchildrenandadolescentslivingwithtype1diabetesinEurope,withapproximately35.1thousandhavingthiscondition.TheUnitedKingdomhadthesecondhighestamount,withroughly31.6thousandyoungpeoplediagnosedwithtype1diabetes.Thisstatisticdisplaysthenumberofchildrenandadolescentswithtype1diabetesinEuropein2021,bycountry.ReadmoreNote(s):Europe;2021;19yearsandyoungerSource(s):InternationalDiabetesFederationHealthexpenditureperpersonwithdiabetesinEuropein2021,bycountry(inU.S.dollars)DiabetescostperpersoninEuropein2021,bycountryAveragespendingperpersoninU.S.dollars4,000

6,000

8,00002,00010,00012,00014,000SwitzerlandNorway12,828.411,166.4Iceland*8,400.78,192.57,844.47,843.37,674.7LuxembourgDenmarkIrelandSwedenGermanyAustriaNetherlandsBelgium6,660.76,574.76,444.96,433.2UnitedKingdomFrance5,859.35,760.115Description:In2021,SwitzerlandhadthehighesthealthexpenditureperpersonwithdiabetesinEurope,withitcostingover12.8thousandU.S.dollarsforeverypersonlivingwithdiabetesinthecountry.Whereas,inRomaniaitcosts930U.S.dollarsonperpersonwithdiabetes.ThisstatisticdisplaysthehealthexpenditureperpersonwithdiabetesinEuropein2021,bycountry.ReadmoreNote(s):Europe;2021;*thedataisbasedonextrapolationfromsimilarcountriesReadmoreSource(s):InternationalDiabetesFederationNumberofdiabetes-relateddeathsinEuropein2021,bycountryDeathsrelatedtodiabetesinEuropein2021,bycountryNumberofdeaths020,00040,00060,00080,000100,000120,000140,000160,000180,000200,000ItalyGermanyUnitedKingdomFrance172,943151,463140,77587,43481,717SpainRomaniaPortugalGreece24,21322,85822,35021,213NetherlandsAustria12,02111,62310,71410,701SwedenBelgiumHungary16Description:In2021,Italyrecordedalmost173thousanddeathsrelatedtodiabetesamongadultsaged20to79years,thehighestnumberofdiabetes-relateddeathsinEurope.Germanyhadsecondhighestnumberofdeathsrelatedtodiabetesthatyearwitharound151.5thousand.ReadmoreNote(s):Europe;2021Source(s):InternationalDiabetesFederationNumberofdiabetesdeathsinEuropein2021,bycountry(per100,000population)RateofdiabetesdeathsinEuropein2021,bycountryNumberofdeathsper100,000population20

25

3005101535404550CzechiaTurkey****Latvia43.432.530.730.129.929.6Russia**Poland*AustriaHungary**Portugal**Italy***2826.124.7Estonia22.221.720.7Germany*LithuaniaDenmark*18.717/statistics/1276113/diabetes-mortality-rate-in-europeIn2021,themortalityratefromdiabetesinCzechiawas42.4per100,000population,thehighestacrosstheselectedEuropeancountries.ThisstatisticdisplaysthenumberofdiabetesdeathsinEuropein2021,bycountry(per100,000population).

ReadmoreNote(s):Europe;2021;*2020data.**2018or2019data.***2016or2017data.****Differenceinmethodologyand2019data.

ReadmoreSource(s):OECDNumberofdiabetesdeathsinEuropein2021,bycountryandgender(per100,000population)RateofdiabetesdeathsinEuropein2021,bycountryandgenderNumberofdeathsper100,000populationFemaleMale300102040506035.9CzechiaAustriaPoland*53.224.825.535.43533.733.328.2Latvia24.3Hungary**Turkey****Portugal**Italy***32.931.431.423.429.72921.219.1Estonia26.725.925.424.6Russia**Germany*Denmark*18.513.818Description:In2021,themortalityratefromdiabetesinCzechiawas53.2per100,000malesand35.9per100,000females.ThesewerethehighestmortalityrateamongmenandwomeninEurope.ThisstatisticdisplaysthenumberofdiabetesdeathsinEuropein2021,bycountryandgender(per100,000population).ReadmoreNote(s):Europe;2021;standardisedrates;*2020data.**2018or2019data.***2016or2017data.****Differenceinmethodologyand2019data.

ReadmoreSource(s):OECDNumberofhospitaladmissionsduetodiabetesinEuropein2021,bycountry(per100,000population)RateofdiabeteshospitaladmissionsinEuropein2021,bycountryAdmissionsper100,000population100050150200250Turkey*GermanySlovakia235172170France*156152LithuaniaRomaniaLuxembourgBelgium*Poland148147140121120AustriaFinlandDenmarkCzechia10210210019Description:In2021,therewereapproximately235hospitaladmissionsper100,000populationinTurkeyduetodiabetes.Furthermore,inthatyeardiabetescausedaround172admissionstohospitalper100,000inGermany.

ReadmoreNote(s):Europe;2021;Adults;*Datafor2019.ReadmoreSource(s):OECDNumberofmajorlowerextremityamputationsamongdiabetessufferersinEuropein2021,bycountry(per100,000population)RateoflowerextremityamputationduetodiabetesinEuropein2021,bycountryAdmissionsper100,000population02468101214161820RomaniaCzechia18.618.4PortugalEstoniaAustria11.110.210.1LatviaPolandGermanySpain8.78.68.57.5UnitedKingdomLithuaniaDenmarkFinland776.45.720Description:In2021,Romaniarecorded18.6majorlowerextremityamputationsforpeoplelivingwithdiabetesper100,000population.Furthermore,inthatyeartherewere18.4lowerlimbamputationsper100,000inCzechia.Sufferersofdiabeteshaveagreaterriskoflowerlegamputation.ReadmoreNote(s):Europe;2021;Adults;*Englandonly.ReadmoreSource(s):OECDCHAPTER

03MedicationuseConsumptionofdrugsusedfordiabetesinDenmarkfrom2011to2021*(inDDDper1,000inhabitants)DiabetespharmaceuticalconsumptioninDenmark2011-2021807060676258.85755.654.75351.851.250.549504030201002011201220132014201520162017201820192020202122Description:TheconsumptionofdrugsusedindiabetesinDenmarkincreasedbyfivedosagesper1,000inhabitantsperday(+8.06percent)in2021.With67dosagesper1,000inhabitantsperday,theconsumptiontherebyreacheditshighestvalueintheobservedperiod.Notably,theconsumptioncontinuouslyincreasedoverthelastyears.ReadmoreNote(s):Denmark;2011to2021Source(s):OECDConsumptionofdrugsusedfordiabetesinFrancefrom2008to2021(inDDDper1,000inhabitants)DiabetespharmaceuticalconsumptioninFrance2008-20211009086.987.485.684.58484.882.481.681.380.28070605040302010074.572.965.762.8200820092010b2011201220132014201520162017201820192020202123Description:In2021,theconsumptionofdrugsusedfordiabetesinFranceincreasedbyalmosttwodosagesper1,000inhabitantsperdaycomparedto2020.With87.4dosagesper1,000inhabitantsperday,theconsumptiontherebyreacheditshighestvalueintheobservedperiod.ThisstatisticdisplaystheconsumptionofdrugsusedfordiabetesinFrancefrom2008to2021.ReadmoreNote(s):France;2008to2021Source(s):OECDConsumptionofdrugsusedfordiabetesper1,000inhabitantsperday*inGermanyfrom2009to2021DiabetesdrugsconsumptioninGermany2009-20211009093.69188.385.983.283.283.683.883.582.682.681.479.4807060504030201002009d2010d2011d2012d2013d2014d2015d2016d2017d2018bd2019d2020d2021d24Description:TheconsumptionofdrugsusedindiabetesinGermanyincreasedby2.6dosagesper1,000inhabitantsperday(+2.86percent)in2021incomparisontothepreviousyear.Therefore,theconsumptioninGermanyreachedapeakin2021with93.6dosagesper1,000inhabitantsperday.ReadmoreNote(s):Germany;2009to2021Source(s):OECDConsumptionofdrugsusedfordiabetesinIcelandfrom2008to2022(inDDDper1,000inhabitants)DiabetespharmaceuticalconsumptioninIceland2008-202270605057.954.851.148.74847.246.544.942.341.938.938.140302010031.728.926.82008200920102011bd2012d2013d2014d2015d2016d2017d2018d2019d2020d2021d2022d25Description:In2022,theconsumptionofdrugsusedindiabetesinIcelandincreasedby3.1dosagesper1,000inhabitantsperday(+5.66percent)since2021.With57.9dosagesper1,000inhabitantsperday,theconsumptiontherebyreacheditshighestvalueintheobservedperiod.Notably,theconsumptioncontinuouslyincreasedoverthelastyears.ReadmoreNote(s):Iceland;2008to2022Source(s):OECDConsumptionrateofantidiabeticsinItalyfrom2014to2022(inDDDper1,000inhabitantsperday)ConsumptionofantidiabeticsinItaly2014-2022807066.964.463.763.161.8626262.362.4605040302010020142015201620172018201920202021202226Description:Between2014and2022,theconsumptionofantidiabeticdrugsincreasedinItaly.Accordingtothedata,in2014about61.8DDDs(dailydefineddoses)wereconsumedper1,000inhabitantsperday.By2022,theconsumptionofantidiabeticsreached66.9DDDsper1,000inhabitantsperday.ThisfigureshowstheconsumptionrateofantidiabeticsinItalyfrom2014to2022(inDDDper1,000inhabitantsperday).ReadmoreNote(s):Italy;2014to2022Source(s):AgenziaItalianadelFarmacoConsumptionofdrugsusedfordiabetesper1,000inhabitantsperday*intheNetherlandsfrom2009to2021DiabetespharmaceuticalconsumptionintheNetherlands2009-2021908078.577.276.977.675.876.275.17575.174.172.972.370.57060504030201002009d2010d2011d2012d2013d2014d2015d2016d2017d2018d2019d2020d2021d27Description:TheconsumptionofdrugsusedindiabetesintheNetherlandssawnosignificantchangesin2021incomparisontothepreviousyear2020andremainedataround78.5dosagesper1,000inhabitantsperday.Nevertheless,2021stillrepresentsapeakintheconsumptionintheNetherlands.ReadmoreNote(s):Netherlands;2009to2021Source(s):OECDConsumptionofdrugsusedindiabetesper1,000inhabitantsperdayinSpainfrom2008to2022DrugsusedindiabetespharmaceuticalconsumptioninSpain2008-20221009088.684.781.379.678.18076.475.172.971.166.466.67060504030201006260.455.8562008d2009d2010d2011d2012d2013d2014bd2015d2016d2017d2018b2019202020212022p28/statistics/782421/drugs-used-in-diabetes-pharmaceutical-consumption-spainIn2022,theconsumptionofdrugsusedindiabetesinSpainincreasedby3.9dosagesper1,000inhabitantsperday(+4.6percent)since2021.Therefore,theconsumptioninSpainreachedapeakin2022with88.6dosagesper1,000inhabitantsperday.ReadmoreNote(s):Spain;2008to2022;defineddailydosageper1,000inhabitantsperdaySource(s):OECDConsumptionofdrugsusedfordiabetesper1,000inhabitantsperday*intheUnitedKingdomfrom2011to2021DiabetespharmaceuticalconsumptionintheUnitedKingdom2011-202110090908070605040302010085.384.784.583.682.379.977.874.274.372.12011d2012d2013bd2014d2015d2016d2017d2018ed2019ed2020ed2021ed29Description:TheconsumptionofdrugsusedindiabetesintheUnitedKingdomincreasedby15.7dosagesper1,000inhabitantsperday(+21.13percent)in2021.Therefore,theconsumptionintheUnitedKingdomreachedapeakin2021with90dosagesper1,000inhabitantsperday.ReadmoreNote(s):UnitedKingdom;2011to2021Source(s):OECDCHAPTER

04RiskfactorsShareofpopulationwhowereoverweightorobeseinEuropein2021,bycountryandgenderShareofoverweightorobesepopulationinEurope2021,bycountryandgenderShareofpopulationoverweightorobeseWomenMen40%0%10%20%30%50%60%70%80%59.3%57.6%59%Romania*Croatia*UnitredKingdomIceland*75%72%68.6%68.3%68.1%49.9%49.3%Czechia*Finland**Slovakia*Greece*Hungary*Poland*53%67%66.8%65.8%49.3%49.4%51.9%65.2%65.1%48.9%48.5%50%Slovenia*Ireland***64.4%63%31Description:Asof2021,approximately69percentofmenand59percentofwomenintheUnitedKingdomconsideredthemselvesoverweightorobese.AcrosstheEuropeancountriesfeatured,overweightandobesitywasmoreprevalentamongmales.

ReadmoreNote(s):Europe;2021;*2019data**2020data***2022dataSelf-reportedoverweightorobeseshare.Releasedaterepresentsthedatefigureswereaccessed.

ReadmoreSource(s):OECDShareofpopulationwhowereoverweightorobeseinEuropein2021,bycountryShareofoverweightorobesepopulationinEurope2021,bycountryShareofpopulationoverweightorobese30%

40%0%10%20%50%60%70%80%Romania*Croatia*UnitedKingdomFinland**Iceland*66.9%63.8%63.8%60%58.5%58.4%58.2%57.7%57.2%56.6%56.5%56.1%56%Czechia*Hungary*Slovakia*Greece*Poland*Slovenia*Turkey*Ireland***32Description:Asof2021,almost64percentofthepopulationintheUnitedKingdomconsideredthemselvesoverweightorobese.AcrosstheEuropeancountriesfeatured,manyhadmorethanhalfoftheirpopulationclassedasoverweightorobese.

ReadmoreNote(s):Europe;2021;*2019data.**2020data.***2022data.Self-reportedoverweightorobeseshare.Releasedaterepresentsthedatefigureswereaccessed.

ReadmoreSource(s):OECDPercapitaconsumptionofsoftdrinksintheEuropeanUnion(EU)from2010to2022(inliterspercapita)SoftdrinkconsumptionpercapitaintheEuropeanUnion(EU)2010-202212098.897.597.59896.596.795.895.31008060402009595.194.492.290.7201020112012201320142015201620172018201920202021202233Description:In2022,theaveragecitizenofanEUmemberstateconsumed98litersofsoftdrinkspercapitaannually.Theheightofsoftdrinkconsumptionwasseenin2011.However,sincethenconsumptionhasfluctuatedsignificantly.ReadmoreNote(s):Europe;2010to2022Source(s):Canadean;UNESDAAnnualconsumptionvolumeofsoftdrinksintheEuropeanUnion(EU)from2013to2022(inmillionliters)AnnualsoftdrinkconsumptionvolumeintheEuropeanUnion(EU)2013-202260,00051,88450,770.350,964.349,780.849,939.949,272.649,297.648,662.548,662.850,00040,00030,00020,00010,000047,817201320142015201620172018201920202021202234/statistics/620207/annual-soft-drink-consumption-in-the-european-unionThisstatisticillustratestheannualconsumptionvolumeofsoftdrinksintheEuropeanUnion(EU)from2013to2022.In2013,49.3billionlitersofsoftdrinkswereconsumedintheEU,whichincreasedtoapproximately51.9billionlitersby2022.ReadmoreNote(s):Europe;2013to2022Source(s):Canadean;UNESDAShareofpeoplewithinsufficientphysicalactivitylevelsinEuropein2021,bycountryShareofpeoplewithinsufficientphysicalactivityinEuropein2021Shareofpeoplewithinsufficientphysicalactivity15%

20%

25%

30%0%5%10%35%40%45%50%PortugalGermanyMalta43.4%42.2%41.7%41.4%ItalyHungaryUnitedKingdomBelgiumRomaniaSlovakiaIreland38.6%35.9%35.7%35.4%34.9%32.7%32.5%32.2%32%PolandSloveniaEstonia35/statistics/1416685/insufficient-physical-activity-levels-in-europeIn2021,itwasfoundthatover40percentofthepopulationhadinsufficientphysicalactivitylevelsinPortugal,Germany,Malta,andItaly.Ontheotherhand,thissharewasbelow20percentinMoldova,Belarus,Finland,Russia,Georgia,andUkraine.ReadmoreNote(s):Europe;2021Source(s):EuropeanSocietyofCardiologyForecastedpopulationofEuropein2020,2025and2050,byagegroup(in1,000s)ForecastedageofpopulationEurope2020-2050202020252050160,000140,000120,000100,00080,00060,00040,00020,00000-45-9

10-14

15-19

20-24

25-29

30-34

35-39

40-44

45-49

50-54

55-59

60-64

65-69

70-74

75-79

80-84

85-89

90-94

95-99

100+36Description:ThisstatisticdisplaystheagedistributionofEuropein2020,withforecastsfor2025and2050.In2020,thelargestagegroupinEuropewerethoseagedbetween35and39,atroughly53millionpeople.By2025however,thelargestagegroupisforecastedtobethoseaged40-44(52.7million)andby2050thoseaged60-64(48.4million).ReadmoreNote(s):Europe;2019Source(s):UnitedNationsCHAPTER

05COVID-19impactDistributionofdiabetessufferers'abilitytomanagetheconditionbeforeandduringtheCOVID-19pandemicandsubsequentrestrictionsinEuropeasof2020AbilitytomanagediabetesbeforeandduringtheCOVID-19pandemicinEurope2020ShareofrespondentsVeryeffectively20%Effectively30%Average40%Notveryeffectively50%

60%Noteffectivelyatall70%0%10%80%90%100%BeforeCOVIDDuringCOVID35%40%22%3%29%32%28%9%2%38Description:AccordingtoasurveyconductedinEuropein2020,peoplelivingwithdiabetesfoundithardertoeffectivelymanagetheconditionduringtheCOVID-19pandemiccomparedtobeforethepandemic.Priortothepandemic,40percentofrespondentsreportedtheycouldeffectivelymanagetheirdiabetes,butthisdroppedto32percentofrespondentsoncethepandemicstuckandthesubsequentlockdownwasenforced.

ReadmoreNote(s):Europe;AugustandOctober2020;3,480respondents;PeoplewithdiabetesortheircarersSource(s):InternationalDiabetesFederationDistributionoftheeffectoftheCOVID-19pandemiconweightandactivitylevelsofdiabetessufferersinEuropeasof2020EffectofCOVID-19onweightandactivitylevelsofdiabetessufferersinEurope2020ShareofrespondentsLostweight10%Stableweight20%Gainedweight30%

40%Lessactive50%Samelevel60%Moreactive70%0%80%90%100%WeightchangeduringpandemicActivitylevelsduringthepandemic17%52%31%57%29%14%39Description:AccordingtoasurveyconductedinEuropein2020,57percentofpeoplelivingwithdiabetesreportedtheywerelessactiveduringtheCOVID-19pandemicandsubsequentlockdown.Furthermore,aroundathirdofdiabetessufferersreportedgainingweightduringthelockdown.ReadmoreNote(s):Europe;AugustandOctober2020;3,087respondents;PeoplewithdiabetesortheircarersSource(s):InternationalDiabetesFederationDistributionoftheeffectoftheCOVID-19pandemiconepisodesofhypoglycemiaandhyperglycemiaofdiabetessufferersinEuropeasof2020EpisodesofhypoglycemiaandhyperglycemiaduringCOVID-19pandemicinEurope2020ShareofrespondentsLessthanusual20%

30%Morethanusual40%Thesamenumber50%

60%None0%10%70%80%90%100%HypoglycemiaSeverehypoglycemiaHyperglycemia13%15%54%18%5%5%17%73%9%25%43%22%40Description:AccordingtoasurveyconductedinEuropein2020,25percentofdiabetessufferersreportedexperiencingmoreepisodesofhyperglycemia(whenbloodsugarlevelsaretoohigh)duringtheCOVID-19pandemicandsubsequentrestrictions.Justoverhalfofrespondentssaidtheysufferedthesameamountofepisodesofhypoglycemia(lowbloodsugarlevels)duringthepandemiccomparedtobefore.

ReadmoreNote(s):Europe;AugustandOctober2020;3,480respondents;PeoplewithdiabetesortheircarersSource(s):InternationalDiabetesFederationDistributionoftheeaseofaccesstomedicationfordiabetessufferersbeforeandduringtheCOVID-19pandemicinEuropeasof2020DiabetesmedicationaccessbeforeandduringCOVID-19pandemicinEurope2020ShareofrespondentsNotatalldifficult20%Notverydifficult30%

40%Noteasynordifficult50%Difficult60%Verydifficult70%0%10%80%90%100%PriortoCOVIDDuringCOVID70%18%10%1%49%21%18%11%2%41Description:AccordingtoasurveyconductedinEuropein2020,70percentofdiabetessufferersreporteditwasnotatalldifficulttoobtaintheirmedicationpriortotheCOVID-19pandemic,althoughthisdroppedtobelow50percentduringthepandemic.Furthermore,11percentofpeoplelivingwithdiabetessaiditwasdifficulttoaccessmedicationduringthepandemic.ReadmoreNote(s):